Ruinian Zheng1, Guowei Lai2, Rongfa Li2, Yanyan Hao1, Limin Cai3, Jun Jia1. 1. Department of Oncology, Dongguan Institute of Clinical Cancer Research, Affiliated Dongguan People's Hospital, Southern Medical University, Dongguan, China. 2. Department of General Surgery, Affiliated Dongguan People's Hospital, Southern Medical University, Dongguan, China. 3. Dongguan Institute of Clinical Cancer Research, Affiliated Dongguan People's Hospital, Southern Medical University, Dongguan, China.
Abstract
BACKGROUND: The minichromosome maintenance (MCM) protein complex is important for DNA replication. Moreover, the expression of specific MCM complex components has been associated with the survival of hepatocellular carcinoma (HCC) patients. However, the expression and functional roles of minichromosome maintenance complex component 4 (MCM4) in HCC development and progression have not yet been explored. We analyzed the expression and clinical significance of MCM4, including its association with liver cancer patient survival. METHODS: Oncomine, UALCAN, and HCCDB (a database of HCC expression atlas) were used to characterize the expression of MCM4 in tumor and normal tissues. The expression of MCM4 at the protein level was confirmed based on immunohistochemistry (IHC) data obtained from the Human Protein Atlas (HPA) database. The level of MCM4 was measured in tumor and adjacent normal tissues by RT-qPCR, western blot and IHC staining. The copy number alterations (CNAs) and mutations in MCM4 were analyzed by cBioPortal, whereas the co-expression genes of MCM4 in HCC were obtained from Oncomine, and used for gene ontology and pathway analysis via the NetworkAnalyst 3.0 tool, to explore the predictive signaling pathway in HCC. RESULTS: The levels of MCM4 messenger (m)RNA and protein were found to be significantly higher in liver cancer tissues than in normal liver tissues. Kaplan-Meier analysis showed that the upregulation of MCM4 was significantly negatively correlated with the survival of HCC patients. CONCLUSIONS: Our data suggest that MCM4 may be used as a potential prognostic marker and therapeutic target for HCC. 2021 Journal of Gastrointestinal Oncology. All rights reserved.
BACKGROUND: The minichromosome maintenance (MCM) protein complex is important for DNA replication. Moreover, the expression of specific MCM complex components has been associated with the survival of hepatocellular carcinoma (HCC) patients. However, the expression and functional roles of minichromosome maintenance complex component 4 (MCM4) in HCC development and progression have not yet been explored. We analyzed the expression and clinical significance of MCM4, including its association with liver cancer patient survival. METHODS: Oncomine, UALCAN, and HCCDB (a database of HCC expression atlas) were used to characterize the expression of MCM4 in tumor and normal tissues. The expression of MCM4 at the protein level was confirmed based on immunohistochemistry (IHC) data obtained from the Human Protein Atlas (HPA) database. The level of MCM4 was measured in tumor and adjacent normal tissues by RT-qPCR, western blot and IHC staining. The copy number alterations (CNAs) and mutations in MCM4 were analyzed by cBioPortal, whereas the co-expression genes of MCM4 in HCC were obtained from Oncomine, and used for gene ontology and pathway analysis via the NetworkAnalyst 3.0 tool, to explore the predictive signaling pathway in HCC. RESULTS: The levels of MCM4 messenger (m)RNA and protein were found to be significantly higher in liver cancer tissues than in normal liver tissues. Kaplan-Meier analysis showed that the upregulation of MCM4 was significantly negatively correlated with the survival of HCC patients. CONCLUSIONS: Our data suggest that MCM4 may be used as a potential prognostic marker and therapeutic target for HCC. 2021 Journal of Gastrointestinal Oncology. All rights reserved.
Authors: Ludmila de F Valverde; Raíza D de Freitas; Thiago de A Pereira; Marina F de Resende; Ivan M G Agra; Jean N Dos Santos; Mitermayer G Dos Reis; Caroline B S Sales; Clarissa A Gurgel Rocha Journal: Appl Immunohistochem Mol Morphol Date: 2018-02
Authors: A Marcell Szász; András Lánczky; Ádám Nagy; Susann Förster; Kim Hark; Jeffrey E Green; Alex Boussioutas; Rita Busuttil; András Szabó; Balázs Győrffy Journal: Oncotarget Date: 2016-08-02
Authors: Xuejiao Ren; Qingning Zhang; Wenyan Guo; Lan Wang; Tao Wu; Wei Zhang; Ming Liu; Dezhi Kong Journal: Front Pharmacol Date: 2022-08-22 Impact factor: 5.988
Authors: Sui Par; Sofia Vaides; Pamela S VanderVere-Carozza; Katherine S Pawelczak; Jason Stewart; John J Turchi Journal: Cancers (Basel) Date: 2021-07-03 Impact factor: 6.639